Target intelligence / Profile preview

Cellular and tissue environment of damaged tendon

Molecular classification
Other
01

Overview

The cellular and tissue environment of a damaged tendon refers to the complex, altered microenvironment characterized by a shift from a highly organized collagenous matrix to a disorganized, hypercellular, and hypervascular state. In this environment, resident tenocytes undergo phenotypic changes, often increasing the production of collagen type III relative to type I, which results in reduced mechanical strength (Millar et al., 2021). The milieu is further defined by an influx of inflammatory mediators, such as IL-1β and TNF-α, and an increased activity of matrix metalloproteinases (MMPs) that degrade the extracellular matrix (Sharma & Maffulli, 2005). Neovascularization is also a hallmark of this environment, often accompanied by nerve ingrowth which contributes to the clinical presentation of pain (D'Addona et al., 2017). While not a single molecular target, this environment serves as a therapeutic landscape where pharmacological agents aim to restore homeostatic mechanotransduction and matrix integrity. Current interventions, including corticosteroids and growth factors, attempt to modulate this environment to favor repair over degeneration (Xu et al., 2020). Understanding the interplay between the various cell types and the biochemical signals within this niche is essential for developing effective regenerative therapies.

Other names
Tendon nicheTendinopathic microenvironmentDamaged tendon milieuTendon extracellular matrix environment
02

Mechanism of action

Modulation of inflammatory cytokines, stimulation of collagen synthesis, and enzymatic degradation of pathological collagen fibers.

03

Biological functions

Extracellular matrix organizationWound healingInflammationMechanotransduction
04

Disease associations

TendinopathyTendon ruptureTendonitis
05

Safety considerations

Risk of tendon rupture with corticosteroid useImpaired healing due to excessive inflammation suppressionPotential for heterotopic ossificationLack of standardization in biologic therapies
06

Interacting drugs

Triamcinolone

4 more in the full profile.

07

Biomarkers

Collagen type III to type I ratioMatrix metalloproteinase-1 (MMP-1)Matrix metalloproteinase-3 (MMP-3)Tenomodulin (TNMD)Scleraxis (SCX)

Beyond the preview

Go deeper on Cellular and tissue environment of damaged tendon.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cellular and tissue environment of damaged tendon.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call